Conference Coverage

Cardiac Monitoring Is Crucial in Neuromuscular Disorder Care


 

FROM AANEM 2024

Pacemakers May Be Considered in Type 1 Myotonic Dystrophy

In type 1 myotonic dystrophy, cardiac conduction abnormalities are seen in two thirds of patients, and sudden cardiac death in up to 30% of patients. “When it is diagnosed, patients do need an ECG at that time, as well as annually,” he said.

Holter monitoring or implantable loop recorders may be recommended, and permanent pacing via an implantable cardioverter-defibrillator might be appropriate.

“Based on the literature to date, the exact timing is not is not clear,” Silvestri said. “The electrophysiologists in my area tend to be very aggressive, thankfully, and treat them fairly soon with pacemakers when we see the first sign of trouble.”

Silvestri disclosed consultant/advisory relationships with argenx, Alexion, Amgen, UCB, Immunovant, and Janssen.

A version of this article appeared on Medscape.com.

Pages

Recommended Reading

Genetic Testing for ALS, Now a Standard, Creates a Path Toward Individualized Care
MDedge Neurology
Promise for Disease-Modifying Therapies to Tame Huntington’s Disease
MDedge Neurology
Diagnosing and Managing Duchenne Muscular Dystrophy: Tips for Practicing Clinicians
MDedge Neurology
Untangling CIDP
MDedge Neurology
Myasthenia Gravis: Patient Choice, Cultural Change
MDedge Neurology
First-in-Class B-Cell Depleting Agent Promising for Myasthenia Gravis
MDedge Neurology
Sustained Control with Investigational Monoclonal Antibody for Myasthenia Gravis
MDedge Neurology
At Last, Treatment Is in Sight for Charcot-Marie-Tooth Disease
MDedge Neurology
Myasthenia Gravis: Similar Symptoms in Relatives Raise Question of Genes
MDedge Neurology
ALS Update: Drug Therapy Continues to Offer Little Benefit
MDedge Neurology